Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
With
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
Age
18–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1\. Diagnosed as stage II-III pancreatic ductal adenocarcinoma patients by pathologic histology;
2\. Pancreatic cancer after radical resection;
3\. Eastern Cooperative Oncology Group Performance Status less than 2;
4\. Without radiotherapy or neoadjuvant chemotherapy;
5\. The man or the gestation and lactation women Age between 18 to 80 years old;
6\. Bone marrow functioned well: ANC more than 1.5\*10\^9/ L, PLT more than 100\*10\^9/LHgb more than 9 g/dL;
7\. Blood biochemical indicators: AST（SGOT）less than 1.5 ULNALT（SGPT）less than 1.5 ULN, TBIL less than 1.5 ULN;
8\. PT and PPT are in normal ranges;
9\. Three months prior to clinical research did not receive any other clinical research trials;
10\. patients are voluntary, and willing to sign informed consent.
You may not be if
1\. Patients with other malignant tumors in the past five years;
2\. Active viral or bacterial infection and cannot be controlled with appropriate anti-infection treatment;
3\. Known as HIV infection, active hepatitis B virus or hepatitis C virus infection;
4\. Known allergy to any kind of component of study drugs;
5\. History of connective tissue disease(Such as lupus, scleroderma, nodular arteritis);
6\. Patients with a history of interstitial pneumoniaSlowly progressive difficulty in breathing and hoose Sarcoidosissilicosis Fibrose pulmonaire idiopathiquehylactic pneumonia or A variety of allergy;
7\. Suffering from mental illness or other illness, such as heart or lung disease, diabetes, etc. that can not be controlled, and can not cope with study treatment and monitoring requirements;
8\. At the same time Patients participate in any other use of interventional medicine clinical research or checkers.
Clareo Health | Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic Cancer
